Gastroenterologie up2date, Table of Contents Gastroenterologie up2date 2012; 08(04): 291-312DOI: 10.1055/s-0032-1325906 Leber/Galle/Pankreas © Georg Thieme Verlag KG Stuttgart · New YorkAktuelle Diagnostik und Therapie der Gallengangskarzinome – Update Authors Marcus W. Wiedmann Sven Jonas Joachim Mössner Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Full Text References Literatur 1 de Groen PC, Gores GJ, LaRusso NF et al. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378 2 Wittekind C, Meyer HJ Hrsg. TNM: Klassifikation maligner Tumoren. 7.. Aufl. Weinheim: Wiley-VCH; 2010: 107-121 3 Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215: 31-38 4 Wittekind C, Tannapfel A. Gallenblasen- und Gallengangskarzinoms – Biologie und Pathologie. Chir Gastroenterol 2004; 20: 242-249 5 Sakamoto E, Nimura Y, Hayakawa N et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg 1998; 227: 405-411 6 West J, Wood H, Logan RF et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 2006; 94: 1751-1758 7 Welzel TM, McGlynn KA, Hsing AW et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-875 8 Strom BL, Soloway RD, Rios-Dalenz JL et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 1995; 76: 1747-1756 9 Chow WH, Johansen C, Gridley G et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999; 79: 640-644 10 Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10: 308-311 11 Bergquist A, Glaumann H, Persson B et al. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 311-316 12 Shaib YH, El-Serag HB, Nooka AK et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-1021 13 Wadsworth CA, Dixon PH, Wong JH et al. Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011; 29: 93-97 14 Zen Y, Adsay NV, Bardadin K et al. Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 2007; 20: 701-709 15 Gouma DJ, Obertop H, Vismans J et al. Progression of a benign epithelial ampullary tumor to adenocarcinoma. Surgery 1987; 101: 501-504 16 Andersen JB, Spee B, Blechacz BR et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012; 142: 1021-1031 17 Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969 18 Fava G, Marzioni M, Benedetti A et al. Molecular pathology of biliary tract cancers. Cancer Lett 2007; 250: 155-167 19 Fingas CD, Bronk SF, Werneburg NW et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011; 54: 2076-2088 20 Olaru AV, Ghiaur G, Yamanaka S et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011; 54: 2089-2098 21 Selaru FM, Olaru AV, Kan T et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49: 1595-1601 22 Borger DR, Tanabe KK, Fan KC et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2011; 17: 72-79 23 Oishi N, Wang XW. Novel therapeutic strategies for targeting liver cancer stem cells. Int J Biol Sci 2011; 7: 517-535 24 Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma?. Oncologist 2006; 11: 913-922 25 Barr Fritcher EG, Kipp BR, Voss JS et al. Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma. Am J Gastroenterol 2011; 106: 2023-2028 26 Lankisch TO, Metzger J, Negm AA et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 2011; 53: 875-884 27 Itoi T, Sofuni A, Itokawa F et al. Peroral cholangioscopic diagnosis of biliary-tract diseases by using narrow-band imaging (with videos). Gastrointest Endosc 2007; 66: 730-736 28 Draganov PV, Lin T, Chauhan S et al. Prospective evaluation of the clinical utility of ERCP-guided cholangiopancreatoscopy with a new direct visualization system. Gastrointest Endosc 2011; 73: 971-979 29 Pohl J, Ell C. Direct transnasal cholangioscopy with ultraslim endoscopes: a one-step intraductal balloon-guided approach. Gastrointest Endosc 2011; 74: 309-316 30 Arvanitakis M, Hookey L, Tessier G et al. Intraductal optical coherence tomography during endoscopic retrograde cholangiopancreatography for investigation of biliary strictures. Endoscopy 2009; 41: 696-701 31 Imazu H, Uchiyama Y, Matsunaga K et al. Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. Scand J Gastroenterol 2011; 45: 732-738 32 Ruys AT, Bennink RJ, van Westreenen HL et al. FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma. HPB (Oxford) 2011; 13: 256-262 33 Ruys AT, Busch OR, Gouma DJ et al. Staging laparoscopy for hilar cholangiocarcinoma: is it still worthwhile?. Ann Surg Oncol 2011; 18: 2647-2653 34 D’Angelica M, Dalal KM, DeMatteo RP et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol 2009; 16: 806-816 35 Tischoff I, Tannapfel A. Hepatozelluläres Karzinom und Cholangiokarzinom – Unterschiedliche Prognose, Pathogenese und Therapie. Zentralbl Chir 2007; 132: 300-305 36 Knuppel M, Kubicka S, Vogel A et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. Gastroenterol Res Pract 2012; 2012: 190708 37 Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006; 45: 856-867 38 Endo I, Gonen M, Yopp AC et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96 39 Stockmann M, Lock JF, Malinowski M et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford) 2010; 12: 139-146 40 Khan SA, Thomas HC, Davidson BR et al. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314 41 Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667 42 Liu F, Li Y, Wei Y et al. Preoperative biliary drainage before resection for hilar cholangiocarcinoma: whether or not? A systematic review. Dig Dis Sci 2011; 56: 663-672 43 Kawakami H, Kondo S, Kuwatani M et al. Preoperative biliary drainage for hilar cholangiocarcinoma: which stent should be selected?. J Hepatobiliary Pancreat Sci 2011; 18: 630-635 44 Jean M, Dua K. Tumors of the ampulla of Vater. Curr Gastroenterol Rep 2003; 5: 171-175 45 Misra S, Chaturvedi A, Misra NC et al. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176 46 Cho SY, Kim SH, Park SJ et al. Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol 2010; 102: 87-93 47 Takada T, Amano H, Yasuda H et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695 48 Wang SJ, Lemieux A, Kalpathy-Cramer J et al. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. J Clin Oncol 2011; 29: 4627-4632 49 Fuller CD, Wang SJ, Choi M et al. Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis. Cancer 2009; 115: 5175-5183 50 Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol 2005; 14: 59-74 51 Speer AG, Cotton PB, Russel RC et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62 52 Will U, Meyer F. [Endoscopic ultrasonography (EUS)-guided transluminal cholangiodrainage (EUCD) – a novel option of interventional endoscopy in the interdiciplinary management of obstructive jaundice]. Zentralbl Chir 2012; 137: 20-31 53 Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 165-175 54 Valek V, Kysela P, Kala Z et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007; 62: 175-179 55 Baron TH. Photodynamic therapy: standard of care for palliation of cholangiocarcinoma?. Clin Gastroenterol Hepatol 2008; 6: 266-267 56 Ortner MEJ, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363 57 Zoepf T, Jakobs R, Arnold JC et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100: 2426-2430 58 Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine vs. gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281 59 Sharma A, Dwary AD, Mohanti BK et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-4586 60 Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600 61 Rao S, Cunningham D, Hawkins RE et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92: 1650-1654 62 Wiedmann MW, Mossner J. Molecular targeted therapy of biliary tract cancer – results of the first clinical studies. Curr Drug Targets 2010; 11: 834-850
